Characterization of a new monoclonal antibody 6G7 that recognizes a unique antigen on myeloid and lymphoid cells.
We generated a monoclonal antibody (mAb) 6G7, which recognizes a 220-kD antigen on selected subpopulations of normal myeloid and lymphoid cells and their malignant counterparts. 6G7 reacts with 90-95% of peripheral blood B cells, 70-80% of CD8(+) cells, 30-35% of CD4(+) cells, 20-40% of monocytes, and 20-40% of CD34(+) cells from bone marrow. 6G7 reacts with leukemic blasts in acute myeloid leukemia (14/16), adult acute lymphoblastic leukemia (ALL) (5/5), pediatric ALL (5/9), chronic lymphocytic leukemia (8/8), follicular lymphoma (7/7), and Burkitt's lymphoma (1/1). Long-term bone marrow culture of 6G7(+/-) cells showed the majority of clonogenic hematopoietic cells were in mAb 6G7 subpopulation. An immunotoxin of 6G7 and ricin A chain was cytotoxic to 6G7(+) leukemia cell lines. mAb 6G7 has potential clinical applications for targeted immunotherapy of both leukemia and lymphoma.
Chen
J
J
Department of Medicine and Cancer Center, University of California, San Diego School of Medicine, La Jolla, CA 92093-0960, USA.
Zhou
J H
JH
Ball
E D
ED
D000328:Adult; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis*; D001402:B-Lymphocytes / Q000276:immunology; D001854:Bone Marrow Cells / Q000276:immunology / Q000473:pathology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002648:Child; D018922:HL-60 Cells; D006801:Humans; D016130:Immunophenotyping; D020014:K562 Cells; D007938:Leukemia / Q000097:blood / Q000276:immunology* / Q000473:pathology; D008214:Lymphocytes / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology*; D009000:Monocytes / Q000276:immunology; D014407:Tumor Cells, Cultured; D020298:U937 Cells
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000954:Antigens, Surface